Estrogen and progesterone receptor expression: Impacts on platinum sensitivity and survival outcomes in high-grade serous ovarian cancer

Abstract

Background: This study aimed to explore the impact of patient-specific factors on the effectiveness of platinum-based chemotherapy in ovarian cancer patients. Specifically, we investigated the relationship between estrogen receptor (ER) and progesterone receptor (PR) expression levels and platinum sensitivity, and how this influenced treatment outcomes and prognosis. We conducted a survival analysis on patients who underwent surgical treatment for serous ovarian cancer and received platinum-based adjuvant therapies.

Methods: This study was a retrospective observational analysis of 171 patients with high-grade serous ovarian cancer. We extracted and analyzed the patients’ clinical data, focusing on platinum sensitivity concerning hormone receptor expression. We also assessed survival outcomes based on receptor expression and platinum resistance.

Results: Our findings revealed that 78.4% (n = 134) of the patients were platinum-sensitive, while 21.6% (n = 37) were platinum-resistant. The expression of hormone receptors showed significant associations with platinum sensitivity, particularly among ER-positive patients (p<0.05). Age, disease stage, preoperative carbohydrate antigen 125 (CA125) levels, and residual tumor size were identified as notable factors influencing both progression-free survival (PFS) and overall survival (OS). In terms of PFS, 88.5% of patients remained free from disease progression after one year, but this percentage dropped to 21% after five years. The average duration of PFS was 35.3 months. As for OS, 93.5% of patients were still alive after one year, but this percentage decreased to 50.5% after five years. The average survival duration was 64 months. Furthermore, platinum resistance was found to be a significant risk factor for disease progression, with a more than fivefold increase in risk (p < 0.001).

Conclusion: Our study identified disease stage progression, ER negativity, and platinum resistance as the primary factors influencing OS. We also found that ER and PR expression played a crucial role in determining the sensitivity to platinum-based chemotherapy in patients with serous ovarian cancer.

Keywords

chemotherapy / hormone receptor / platinum sensitivity / serous ovarian cancer

References

[1] Cathcart AM, Nezhat FR, Emerson J, Pejovic T, Nezhat CH, Nezhat CR. Adnexal masses during pregnancy: diagnosis, treatment, and prognosis. Am J Obstet Gynecol. 2023;228(6):601-612.

[2] Kurnit KC, Frumovitz M. Primary mucinous ovarian cancer: options for surgery and chemotherapy. Int J Gynecol Cancer. 2022;32:1455-1462.

[3] Porter RL, Matulonis UA. Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer. Expert Rev Anticancer Ther. 2023;23(8):783-796.

[4] Li X, Feng Y, Lin JF, Billig H, Shao R. Endometrial progesterone resistance and PCOS. J Biomed Sci. 2014;21(1):2.

[5] Mungenast F, Thalhammer T. Estrogen biosynthesis and action in ovarian cancer. Front Endocrinol. 2014;5:192.

[6] Troisi R, Bjørge T, Gissler M, et al. The role of pregnancy, perinatal factors and hormones in maternal cancer risk: a review of the evidence. J Intern Med. 2018;283(5):430-445.

[7] Vetter M, Stadlmann S, Bischof E, et al. Hormone receptor expression in primary and recurrent high-grade serous ovarian cancer and its implications in early maintenance treatment. Int J Mol Sci. 2022;23(22):14242.

[8] Tan J, Song C, Wang D, et al. Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer. Biosci Rep. 2021;41(5):BSR20210478.

[9] Demir L, Yigit S, Sadullahoglu C, et al. Hormone receptor, HER2/NEU and EGFR expression in ovarian carcinoma—is here a prognostic phenotype? Asian Pac J Cancer Prev. 2014;15(22):9739-9745.

[10] Feng Z, Wen H, Bi R, et al. A clinically applicable molecular classification for high-grade serous ovarian cancer based on hormone receptor expression. Sci Rep. 2016;6:25408.

[11] Le Page C, Chung J, Rahimi K, Köbel M, Provencher D, Mes-Masson AM. Exploring the clinical impact of predictive biomarkers in serous ovarian carcinomas. Curr Drug Targets. 2020;21(10):974-995.

[12] George A, McLachlan J, Tunariu N, et al. The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole. BMC Cancer. 2017;17(1):456.

[13] da Costa AABA, Baiocchi G. Genomic profiling of platinum-resistant ovarian cancer: the road into druggable targets. Sem Cancer Biol. 2021;77:29-41.

[14] Muggia F, Bonetti A. History of intraperitoneal platinum drug delivery for ovarian cancer and its future applications. Cancer Drug Resist. 2021;4(2):453-462.

[15] Patel A, Kalachand R, Busschots S, et al. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2022;7(7):CDd008766.

[16] Cao J, Hacking S, Chavarria-Bernal HD, Bhuiya TA, Khutti S. Androgen receptor immunohistochemical expression in undifferentiated/dedifferentiated endometrial carcinoma. Int J Gynecol Pathol. 2022;41(1):28-34.

[17] Wilhite AM, Baca Y, Xiu J, et al. Molecular profiles of endometrial cancer tumors among Black patients. Gynecol Oncol. 2022;166(1):108-116.

[18] Murali R, Balasubramaniam V, Srinivas S, et al. Deregulated metabolic pathways in ovarian cancer: cause and consequence. Metabolites. 2023;13(4):560.

[19] Folsom SM, Berger J, Soong TR, Rangaswamy B. Comprehensive review of serous tumors of tubo-ovarian origin: clinical behavior, pathological correlation, current molecular updates, and imaging manifestations. Curr Probl Diagn Radiol. 2023;52(5):425-438.

[20] Hollis RL. Molecular characteristics and clinical behaviour of epithelial ovarian cancers. Cancer Lett. 2023;555:216057.

[21] Hollis RL, Thomson JP, van Baal J, et al. Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma. Sci Rep. 2023;13(1):7681.

[22] Petrillo M, Sozzi G, Dessole M, et al. The role of surgery in platinum-resistant ovarian cancer: a call to the scientific community. Sem Cancer Biol. 2021;77:194-202.

[23] Shafrir AL, Rice MS, Gupta M, et al. The association between reproductive and hormonal factors and ovarian cancer by estrogen-α and progesterone receptor status. Gynecol Oncol. 2016;143(3):628-635.

RIGHTS & PERMISSIONS

2024 The Author(s). Malignancy Spectrum published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.